Valuation: Novacyt

Market Cap 37.27M 43.48M 34.86M 31.87M 60.15M 4.16B 60.79M 413M 160M 2.09B 163M 160M 6.92B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 39.22M 45.77M 36.69M 33.55M 63.3M 4.38B 63.98M 434M 169M 2.2B 172M 168M 7.28B EV / Sales 2026 *
1.28x
EV / Sales 2027 * 1.21x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day-0.19%
1 week-5.87%
Current month+20.28%
1 month+14.00%
3 months-22.27%
6 months+28.73%
Current year+31.20%
1 week 0.48
Extreme 0.4765
0.55
1 month 0.42
Extreme 0.415
0.56
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 01/05/2024
Director of Finance/CFO 44 01/01/2020
Chief Operating Officer - 01/11/2021
Director TitleAgeSince
Director/Board Member 75 03/07/2006
Director/Board Member 60 27/06/2017
Director/Board Member 44 02/01/2024
Date Insider Type Main position Quantity % Market Cap.
4/23/24 A Free

Chief Executive Officer

946,475 1.3401%
4/23/24 A Free

Chief Financial Officer

391,645 0.5545%
4/23/24 A Free

Chief Technology Officer

465,078 0.6585%
Change 5-day change 1-year change 3-year change Capi.($)
-0.19%-5.87%+5.99%-40.76% 43.48M
-1.39%+1.91%-41.59%-41.18% 622M
-2.02%-17.21%+80.77% - 335M
0.00%-1.82%-29.43%-3.53% 137M
-2.00%-7.98%-19.01%+24.05% 77.91M
Average -1.12%-3.62%-0.65%-15.36% 243.2M
Weighted average by Cap. -1.40%-2.52%-3.35%-29.53%

Financials

2026 *2027 *
Net sales 30.52M 35.62M 28.56M 26.11M 49.27M 3.41B 49.79M 338M 131M 1.71B 134M 131M 5.67B 34.86M 40.68M 32.61M 29.82M 56.27M 3.9B 56.86M 386M 150M 1.96B 153M 149M 6.47B
Net income - -
Net Debt 1.96M 2.28M 1.83M 1.67M 3.16M 219M 3.19M 21.65M 8.42M 110M 8.57M 8.38M 363M 4.84M 5.65M 4.53M 4.14M 7.81M 541M 7.9M 53.6M 20.84M 272M 21.21M 20.75M 899M
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
216
Date Price Change Volume
25/08/26 0.5130 -0.19% 25,803
24/08/26 €0.5140 -3.20% 203,070
21/08/26 €0.5310 +8.37% 750,774
20/08/26 €0.4900 -4.48% 346,416
19/08/26 €0.5130 -5.87% 576,328

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALNOV Stock